NEW YORK, April 2 -- Aclara BioSciences and Amersham Biosciences today announced a joint marketing agreement for DNA analysis equipment and chemistries.
Financial details were not provided.
The non-exclusive agreement joins Amersham Biosciences MegaBace DNA analysis system, and Alcara's eTag assay system, as complementary systems. The companies will continue to sell and support the systems independently, but will promote the other's products for their respective platforms.